SCHEMBL5484266

SCHEMBL5484266

COc1ccc(C)cc1NC(=O)Nc1ccc(N2CCN(C(=O)Nc3ccc(F)cc3F)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.58
SMN1; SMN2 Q16637 4/20 0.58
ALDH1A1 P00352 5/20 0.56
LMNA P02545 3/20 0.56
NPSR1 Q6W5P4 1/20 0.56
TP53 P04637 3/20 0.53
HTR1A P08908 1/20 0.53
HTR1D P28221 1/20 0.53
HTR1B P28222 1/20 0.53
HTR2A P28223 1/20 0.53
RAB9A P51151 5/20 0.52
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
NPC1 O15118 3/20 0.52
GAA P10253 1/20 0.52
MAPK1 P28482 1/20 0.52
RBP4 P02753 1/20 0.50
HTT P42858 1/20 0.48
PKM P14618 1/20 0.48
GRIN2B Q13224 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5473636 0.87 MAPT (0.51) MAPTSMN1; SMN2ALDH1A1LMNANPSR1
SCHEMBL5464801 0.85 MAPT (0.68) MAPTSMN1; SMN2ALDH1A1LMNATP53
SCHEMBL5458584 0.85 MAPT (0.53) MAPTSMN1; SMN2ALDH1A1LMNANPSR1
SCHEMBL5455945 0.85 MAPT (0.57) MAPTSMN1; SMN2ALDH1A1LMNANPSR1
SCHEMBL5455975 0.84 MAPT (0.58) MAPTSMN1; SMN2ALDH1A1LMNANPSR1
SCHEMBL5450980 0.84 HTR1A (0.55) MAPTSMN1; SMN2ALDH1A1LMNANPSR1
SCHEMBL5456010 0.83 MAPT (0.51) MAPTSMN1; SMN2ALDH1A1LMNANPSR1
SCHEMBL5462082 0.83 MAPT (0.52) MAPTSMN1; SMN2ALDH1A1LMNANPSR1
SCHEMBL5453431 0.83 RBP4 (0.54) MAPTSMN1; SMN2ALDH1A1LMNANPSR1
SCHEMBL5465476 0.83 MAPT (0.49) MAPTSMN1; SMN2ALDH1A1LMNANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 MAPT 758/4885SMN1; SMN2 4424/4885ALDH1A1 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.